Navigation Links
CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment
Date:7/22/2009

MENLO PARK, Calif., July 22 /PRNewswire/ -- Apieron, Inc. said today that CareFirst BlueCross BlueShield has adopted a positive coverage policy for the measurement of exhaled nitric oxide (eNO). The Medical Directors of CareFirst determined that the published, peer-reviewed evidence is sufficient to support benefit coverage for the treatment of asthma. The policy, effective July 20, 2009, states the measurement of exhaled nitric oxide is considered medically necessary in the management of asthma patients. CareFirst is the largest health care insurer in the Mid-Atlantic region, serving nearly 3.4 million members in Maryland, District of Columbia and portions of Virginia.

"In clinical practice, adopters of eNO monitoring have reported that eNO is predictive of asthma in patients with normal lung function, predictive of lack of compliance with medication regimens, and predictive of response to inhaled corticoid steroids," said Ms. Holly McGarraugh, Apieron CEO & President. "We are delighted that CareFirst has recognized the valuable impact that eNO measurement can have on asthma treatment. We are working to encourage similar coverage policies among private payers and managed care organizations across the country."

In a separate development, an official joint statement from the European Respiratory Society and the American Thoracic Society on June 25, 2009 included the recommendation that eNO be used as a biomarker for heightened concentrations of cells associated with asthma and allergy, and in evaluations of response to inhaled corticosteroid (ICS) treatments. The authors stated that eNO is a valuable tool to manage ICS and monitor its effects.

The American Thoracic Society is presently developing guidelines for eNO monitoring.

About the Insight eNO System

The Insight eNO System has been available for use in the physician's office since March 2008. The system uses a proprietary biosensor technology to measure exhaled nitric oxide, a well established indicator of asthma severity and steroid responsive airway inflammation. Measuring eNO and determining the level of airway inflammation can help clinicians more closely manage their patients' inflammatory condition and therefore more precisely titrate medications, which can lead to fewer exacerbations.

About Apieron, Inc.

Apieron, Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use, non-invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.

    Contact:
    Steve Bubrick
    (650) 838-8209


'/>"/>
SOURCE Apieron, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
2. Video: New Research Discovers Independent Brain Networks Control Human Walking
3. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
4. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
5. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
6. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
9. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
10. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
11. The Childrens Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohns Disease Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):